The number of druggable tumor-specific molecular aberrations has grown substantially in
the past decade, with a significant survival benefit obtained from biomarker matching …

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing
efforts for its early detection by screening populations at risk, the majority of lung cancer …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

Background Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …

Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD).
However, the long-term application of gefitinib usually leads to acquired drug resistance in …

Introduction Anti-EGFR agents are standard treatments for patients with EGFR-mutant
advanced NSCLC. The feasibility of combining erlotinib or gefitinib with the anti …

Introducción El cáncer de pulmón es un importante problema de salud pública. Constituye
la segunda causa de muerte por cáncer en el mundo y se asocia a tasas de supervivencia …

The discoveries of cancer research have been translated into the clinical management of
lung cancer patients. So far, the approach of targeted therapy that is directed towards certain …

Ferroptosis is an iron-dependent regulated form of cell death caused by excessive lipid
peroxidation. This form of cell death differed from known forms of cell death in morphological …

Simple Summary Lung cancer is the major cause of cancer-related deaths worldwide. The
development of targeted therapies has dramatically improved the outcome of lung cancer …